Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions

Glioblastoma is a highly aggressive form of brain cancer characterized by the abundance of myeloid lineage cells in the tumor microenvironment. Tumor-associated macrophages and microglia (TAM) and myeloid-derived suppressor cells (MDSCs), play a pivotal role in promoting immune suppression and tumor progression. Oncolytic viruses (OVs) are self-amplifying cytotoxic agents that can stimulate local anti-tumor immune responses and have the potential to suppress immunosuppressive myeloid cells and recruit tumor-infiltrating T lymphocytes (TILs) to the tumor site, leading to an adaptive immune response against tumors. However, the impact of OV therapy on the tumor-resident myeloid population and the subsequent immune responses are not yet fully understood. This review provides an overview of how TAM and MDSC respond to different types of OVs, and combination therapeutics that target the myeloid population to promote anti-tumor immune responses in the glioma microenvironment.

[1]  H. Kaufman,et al.  Therapy with oncolytic viruses: progress and challenges , 2023, Nature Reviews Clinical Oncology.

[2]  K. Azadmanesh,et al.  Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand? , 2022, Cancer Cell International.

[3]  M. Boldrini,et al.  Spatial profiling of chromatin accessibility in mouse and human tissues , 2022, Nature.

[4]  T. Todo,et al.  Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial , 2022, Nature Medicine.

[5]  J. Christie,et al.  Treat and repeat: oncolytic virus therapy for brain cancer , 2022, Nature Medicine.

[6]  G. Dharmadhikari,et al.  Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. , 2022, The New England journal of medicine.

[7]  Maohui Luo,et al.  A map of the spatial distribution and tumour‐associated macrophage states in glioblastoma and grade 4 IDH‐mutant astrocytoma , 2022, The Journal of pathology.

[8]  A. Desjardins,et al.  Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice , 2022, Neurotherapeutics.

[9]  Binzhi Qian,et al.  Macrophage diversity in cancer revisited in the era of single-cell omics. , 2022, Trends in immunology.

[10]  J. Hossain,et al.  Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities , 2022, Cancers.

[11]  Maohui Luo,et al.  Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model , 2022, Virology Journal.

[12]  G. Castelo-Branco,et al.  Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level , 2022, Science.

[13]  A. Planas,et al.  Protein Expression of the Microglial Marker Tmem119 Decreases in Association With Morphological Changes and Location in a Mouse Model of Traumatic Brain Injury , 2022, Frontiers in Cellular Neuroscience.

[14]  E. Chiocca,et al.  Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword , 2022, International journal of molecular sciences.

[15]  Zhongming Zhao,et al.  NOTCH induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates anti-tumor immunotherapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  J. Gumin,et al.  Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry , 2021, Journal for ImmunoTherapy of Cancer.

[17]  R. Bjerkvig,et al.  Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors , 2021, Neuro-oncology.

[18]  F. Lang,et al.  Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors , 2021, Journal of NeuroInterventional Surgery.

[19]  M. Hidalgo,et al.  VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects , 2021, Journal for ImmunoTherapy of Cancer.

[20]  M. Caligiuri,et al.  An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma , 2021, Nature Communications.

[21]  Jian Hu,et al.  Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition. , 2021, Neuro-oncology.

[22]  J. Virga,et al.  Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity , 2021, International journal of molecular sciences.

[23]  M. Lamfers,et al.  The Multifaceted Role of Macrophages in Oncolytic Virotherapy , 2021, Viruses.

[24]  T. D. de Gruijl,et al.  Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 , 2021, Frontiers in Immunology.

[25]  Xiao Liang,et al.  Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy , 2021, Frontiers in Cell and Developmental Biology.

[26]  M. Röcken,et al.  Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma , 2021, Translational oncology.

[27]  Atique U. Ahmed,et al.  Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. , 2021, The Lancet. Oncology.

[28]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[29]  D. Aminin,et al.  Macrophages as a “weapon” in anticancer cellular immunotherapy , 2021, The Kaohsiung journal of medical sciences.

[30]  Jiong Cai,et al.  Cytotoxic T lymphocyte‐associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells , 2021, International journal of cancer.

[31]  M. Sanson,et al.  SLIT2-ROBO signaling in tumor-associated microglia/macrophages drives glioblastoma immunosuppression and vascular dysmorphia , 2021, bioRxiv.

[32]  J. Johnston,et al.  Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. , 2021, The New England journal of medicine.

[33]  S. Reich-Zeliger,et al.  P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression , 2021, Nature Communications.

[34]  Fusheng Liu,et al.  P4HA1 Down-Regulation Inhibits Glioma Invasiveness by Promoting M1 Microglia Polarization , 2021, OncoTargets and therapy.

[35]  A. Heimberger,et al.  FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. , 2021, Cancer letters.

[36]  Anirban Ghosh,et al.  Dichotomy in Growth and Invasion from Low- to High-Grade Glioma Cellular Variants , 2021, Cellular and Molecular Neurobiology.

[37]  M. Borad,et al.  Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. , 2021, JCO precision oncology.

[38]  H. Fine,et al.  Diffuse Glioma Heterogeneity and Its Therapeutic Implications. , 2021, Cancer discovery.

[39]  D. Bartlett,et al.  IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity , 2021, Cancer Immunology, Immunotherapy.

[40]  M. Ivan,et al.  Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report. , 2021, Neurosurgical focus.

[41]  J. Egen,et al.  Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment , 2021, Cancer Immunology, Immunotherapy.

[42]  T. D. de Gruijl,et al.  Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma. , 2021, Human gene therapy.

[43]  L. Xue,et al.  Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer , 2021, Journal for ImmunoTherapy of Cancer.

[44]  N. Hockstein,et al.  Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer , 2020, Cell reports.

[45]  R. Eftimie,et al.  Oncolytic viral therapies and the delicate balance between virus-macrophage-tumour interactions: A mathematical approach. , 2020, Mathematical biosciences and engineering : MBE.

[46]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[47]  A. Yang,et al.  Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity , 2020, Molecular Cancer Therapeutics.

[48]  Alexander P. Landry,et al.  Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma , 2020, Scientific Reports.

[49]  E. Shusta,et al.  Blood–Brain Barrier Modulation to Improve Glioma Drug Delivery , 2020, Pharmaceutics.

[50]  G. McFadden,et al.  Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses , 2020, Biomedicines.

[51]  Steven J. M. Jones,et al.  Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression , 2020, Nature Communications.

[52]  Á. Ayuso-Sacido,et al.  Oncolytic Virotherapy in Glioma Tumors , 2020, International journal of molecular sciences.

[53]  A. Iavarone,et al.  ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages , 2020, Nature Communications.

[54]  Fusheng Liu,et al.  Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas , 2020, Cell Death & Disease.

[55]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[56]  B. Becher,et al.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.

[57]  A. Loskog,et al.  The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses , 2020, Frontiers in Immunology.

[58]  H. Neufeld,et al.  Oncolytic vesicular stomatitis viruses selectively target M2 macrophages. , 2020, Virus research.

[59]  J. Luan,et al.  The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment , 2020, Frontiers in Immunology.

[60]  S. Johnston,et al.  M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations , 2020, EBioMedicine.

[61]  L. Seymour,et al.  Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion , 2020, Cancers.

[62]  E. Chiocca,et al.  Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene , 2020, Molecular therapy. Methods & clinical development.

[63]  C. Weidong,et al.  Macrophage M1/M2 polarization. , 2020, European journal of pharmacology.

[64]  S. H. van der Burg,et al.  Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. , 2020, Trends in immunology.

[65]  N. Xia,et al.  Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade , 2020, Cancer immunology research.

[66]  J. Rich,et al.  Glioblastoma Stem Cells: Driving Resilience through Chaos. , 2020, Trends in cancer.

[67]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[68]  R. Wilkinson,et al.  Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro , 2020, Cancer Immunology, Immunotherapy.

[69]  J. Klode,et al.  Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain , 2020, Frontiers in Immunology.

[70]  Yi Wu,et al.  Embelin Promotes Oncolytic Vaccinia Virus-Mediated Antitumor Immunity Through Disruption of IL-6/STAT3 Signaling in Lymphoma , 2020, OncoTargets and therapy.

[71]  Hsin-Ell Wang,et al.  Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors , 2020, Journal of neuro-oncology.

[72]  H. Keyvani,et al.  Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment , 2020, Virology Journal.

[73]  N. Matsumura,et al.  Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment , 2020, British Journal of Cancer.

[74]  Kaitai Zhang,et al.  oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity , 2020, Molecular therapy oncolytics.

[75]  M. Essand,et al.  Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer , 2020, Cell Death & Disease.

[76]  Junhua Wu,et al.  Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma , 2019, British Journal of Cancer.

[77]  A. van Dam,et al.  Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment , 2019, Acta Neuropathologica Communications.

[78]  L. Walsh,et al.  Microenvironmental Heterogeneity in Brain Malignancies , 2019, Front. Immunol..

[79]  A. Boissonnas,et al.  Ontogeny of Tumor-Associated Macrophages , 2019, Front. Immunol..

[80]  D. J. Doty,et al.  Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation , 2019, Journal of Neuroinflammation.

[81]  Atique U. Ahmed,et al.  HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma , 2019, Cell reports.

[82]  K. Bockhorst,et al.  Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966 , 2019, Molecular Cancer Therapeutics.

[83]  Jiwu Wei,et al.  Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma , 2019, Molecular therapy oncolytics.

[84]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[85]  Yuquan Wei,et al.  Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[86]  Zhiwei Chen,et al.  Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression , 2018, Oncoimmunology.

[87]  Quadri,et al.  Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo , 2019 .

[88]  J. Stewart,et al.  Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. , 2019, The Journal of surgical research.

[89]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[90]  B. J. Van den Eynde,et al.  Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism , 2018, Cancer Immunology, Immunotherapy.

[91]  W. Goins,et al.  Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment , 2018, Molecular therapy oncolytics.

[92]  A. Kleijn,et al.  Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment , 2018, Neuro-oncology.

[93]  T. Luider,et al.  Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors , 2018, Oncotarget.

[94]  J. Kzhyshkowska,et al.  Monocytes and Macrophages as Viral Targets and Reservoirs , 2018, International journal of molecular sciences.

[95]  B. Nelson,et al.  Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[96]  C. Bettegowda,et al.  Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.

[97]  John H. Sampson,et al.  Recurrent Glioblastoma Treated with Recombinant Poliovirus , 2018, The New England journal of medicine.

[98]  Q. Gao,et al.  Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells , 2018, Clinical and Experimental Medicine.

[99]  D. Meruelo,et al.  Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity , 2018, Molecular therapy oncolytics.

[100]  Hongwei Liang,et al.  Arginase‐1 is neither constitutively expressed in nor required for myeloid‐derived suppressor cell‐mediated inhibition of T‐cell proliferation , 2018, European journal of immunology.

[101]  K. Ishii,et al.  Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner , 2018, The Journal of Immunology.

[102]  Min-jung Park,et al.  Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice , 2018, Scientific Reports.

[103]  K. Aldape,et al.  Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Matija Snuderl,et al.  Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. , 2018, Biomaterials.

[105]  Steffen Dettling,et al.  When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma , 2018, International journal of molecular sciences.

[106]  S. Hansen,et al.  Tumour‐associated microglia/macrophages predict poor prognosis in high‐grade gliomas and correlate with an aggressive tumour subtype , 2018, Neuropathology and applied neurobiology.

[107]  H. Frieboes,et al.  Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment , 2018, Journal of Immunotherapy for Cancer.

[108]  Leland S. Hu,et al.  Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.

[109]  P. Rennie,et al.  Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3. , 2018, Cancer research.

[110]  Yun Xu,et al.  EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment , 2017, Journal of Neuroinflammation.

[111]  J. Markert,et al.  Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002 , 2017, Molecular therapy oncolytics.

[112]  A. Unterberg,et al.  Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[114]  S. Gygi,et al.  Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages , 2017, Journal of proteome research.

[115]  Z. Guo,et al.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.

[116]  B. Kamińska,et al.  Immune microenvironment of gliomas , 2017, Laboratory Investigation.

[117]  N. Ratner,et al.  Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation , 2017, Oncotarget.

[118]  P. Lowenstein,et al.  Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  A. Szalay,et al.  Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells , 2016, Journal of Translational Medicine.

[120]  Atique U. Ahmed,et al.  CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. , 2016, Cancer research.

[121]  J. Rojas,et al.  Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. , 2016, Cancer cell.

[122]  T. Cripe,et al.  Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? , 2016, Biomedicines.

[123]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[124]  J. R. de Sousa,et al.  In situ expression of M2 macrophage subpopulation in leprosy skin lesions. , 2016, Acta tropica.

[125]  I. Weissman,et al.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo , 2016, PloS one.

[126]  M. Prados,et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.

[127]  I. Melero,et al.  Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) , 2016, Clinical Cancer Research.

[128]  Ginu A. Thomas,et al.  Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. , 2016, JCI insight.

[129]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[130]  J. Merchan,et al.  Targeting tumor vasculature through oncolytic virotherapy: recent advances , 2015, Oncolytic virotherapy.

[131]  S. Rohn,et al.  Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps , 2015, Journal of Translational Medicine.

[132]  H. Wishart,et al.  Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. , 2015, Neuro-oncology.

[133]  Patrick W. Lee,et al.  Newly Recruited CD11b+, GR-1+, Ly6Chigh Myeloid Cells Augment Tumor-Associated Immunosuppression Immediately following the Therapeutic Administration of Oncolytic Reovirus , 2015, The Journal of Immunology.

[134]  M. Lesniak,et al.  Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy , 2015, Oncoimmunology.

[135]  M. Caligiuri,et al.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment , 2015, Clinical Cancer Research.

[136]  A. Garg,et al.  Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death , 2015, International journal of cancer.

[137]  E. Lattime,et al.  The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy , 2015, Cancer Gene Therapy.

[138]  William A. Flavahan,et al.  Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth , 2014, Nature Cell Biology.

[139]  M. Berger,et al.  Survival and low-grade glioma: the emergence of genetic information. , 2015, Neurosurgical focus.

[140]  M. Caligiuri,et al.  Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  B. Seliger,et al.  Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.

[142]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[143]  P. Marcato,et al.  Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms , 2013, British Journal of Cancer.

[144]  Y. Kaneda,et al.  Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. , 2013, Clinical immunology.

[145]  David E. Anderson,et al.  Tumor-Associated Macrophages in Glioma: Friend or Foe? , 2013, Journal of oncology.

[146]  S. Singhal,et al.  Myeloid derived suppressor cells , 2013, Oncoimmunology.

[147]  Y. Nishiyama,et al.  Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models , 2013, International journal of cancer.

[148]  P. Marcato,et al.  Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[149]  D. Begley,et al.  Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[150]  A. Cerwenka,et al.  Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth , 2012, The Journal of Immunology.

[151]  A. Hemminki,et al.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[152]  Xiaopei Huang,et al.  NK Cell Response to Vaccinia Virus Is Regulated by Myeloid-Derived Suppressor Cells , 2012, The Journal of Immunology.

[153]  M. von Knebel Doeberitz,et al.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.

[154]  J. Lišková,et al.  Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells. , 2011, Virus research.

[155]  Fei Li,et al.  Glioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma , 2011, Journal of Neuroimmunology.

[156]  Guangjian Huang,et al.  Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function , 2011, Scandinavian journal of gastroenterology.

[157]  A. Heimberger,et al.  Glioma cancer stem cells induce immunosuppressive macrophages/microglia. , 2010, Neuro-oncology.

[158]  R. Zinkernagel,et al.  Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon‐I‐dependent manner in mice , 2010, Hepatology.

[159]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[160]  F. Marincola,et al.  The complex role of B7 molecules in tumor immunology. , 2008, Trends in molecular medicine.

[161]  E. Chiocca,et al.  Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[162]  D. Brat,et al.  Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. , 2007, Cancer research.

[163]  T. Chou,et al.  5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.

[164]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[165]  M. Caligiuri,et al.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[166]  J. Markert,et al.  Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12 , 2005, Cancer Gene Therapy.

[167]  H. Federoff,et al.  Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases , 2004, Annals of surgery.

[168]  M. Esteban,et al.  Vaccinia virus induces apoptosis of infected macrophages. , 2002, The Journal of general virology.

[169]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[170]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[171]  R. Singaravelu,et al.  Oncolytic Viruses , 2021, Nature.